NYEE HomeThe New York Eye and Ear Infirmary
Patient InfoHealthcare ProfessionalsSpecialties & ServicesSupport NYEEAbout Us
  Current Research
Clinical Trials in Ophthalmology
Ophthalmology
Research

Otolaryngology
Research

Pathology
& Laboratory Medicine
Research

Plastic &
Reconstructive
Surgery
Research

Institutional
Review Board
(IRB)

 
printer-friendly version of this pagePrinter-Friendly Page large print version of this pageLarge Print Version 

A Phase 3, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis® compared with Lucentis® monotherapy every 4 weeks in patients with Exudative Age-Related Macular Degeneration (AMD) - ACU301B


Principal Investigator: Richard Rosen, MD

Enrollment Status: Open Enrollment

Objective:  To evaluate the efficacy of intravitreal bevasiranib sodium as maintenance therapy for Age-Related Macular Degeneration following initiation of anti-VEGF therapy with 3 doses of Lucentis®

Eligibility: 

Contact Information:  Julie Paa, CRC (212) 979-4672; Katy Tai, CR Manager (212) 979-4251

 

Home > Current Research > Clinical Trials in Ophthalmology > A PHASE 3, RANDOMIZED, DOUBLE-MASKED, PARALLEL-ASSIGNMENT STUDY OF INTRAVITREAL BEVASIRANIB SODIUM, ADMINISTERED EVERY 8 OR 12 WEEKS AS MAINTENANCE THERAPY FOLLOWING THREE INJECTIONS OF LUCENTIS® COMPARED WITH LUCENTIS® MONOTHERAPY EVERY 4 WEEKS IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION (AMD) - ACU301B